Kamada (NASDAQ: KMDA) sets May 13 call on Q1 2026 results
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Kamada Ltd. filed a Form 6-K to announce that it will release financial results for the first quarter ended March 31, 2026, before the U.S. market open on May 13, 2026. Management will host a conference call that day at 8:30am Eastern Time for investors and analysts.
The company is a global biopharmaceutical business focused on specialty plasma-derived therapies for rare and serious conditions. Its strategy centers on organic growth of its commercial portfolio, in-licensing and distribution in Israel and the MENA region, expanding plasma collection operations, and pursuing mergers, acquisitions, and collaboration opportunities. FIMI Opportunity Funds is the controlling shareholder, holding approximately 38% of the outstanding ordinary shares.
Positive
- None.
Negative
- None.
Key Figures
Results release date: May 13, 2026
Quarter end date: March 31, 2026
Conference call time: 8:30am Eastern Time
+3 more
6 metrics
Results release date
May 13, 2026
First quarter 2026 financial results announcement
Quarter end date
March 31, 2026
Quarter for which results will be reported
Conference call time
8:30am Eastern Time
Time of May 13, 2026 investment community call
Conference ID
13760232
Dial-in conference identification code for the call
Controlling shareholder stake
Approximately 38% of ordinary shares
FIMI Opportunity Funds beneficial ownership
Plasma collection centers
3 FDA-approved centers
Owned in Beaumont, Houston, and San Antonio, Texas
Key Terms
plasma-derived therapies, hyper-immune plasma, biosimilar products, controlling shareholder, +1 more
5 terms
plasma-derived therapies medical
"a leader in the specialty plasma-derived therapies field"
Plasma-derived therapies are medical products made from proteins extracted from donated blood plasma, used to treat immune deficiencies, bleeding disorders and other chronic conditions. Think of them like concentrated ingredients pulled from a large pot of soup to make a targeted remedy; their manufacture depends on steady donations, complex processing and strict regulation. For investors, that means revenue can be recurring and resilient but also sensitive to supply bottlenecks, regulatory changes and pricing pressures.
hyper-immune plasma medical
"to support its increasing demand for hyper-immune plasma"
biosimilar products medical
"including the launch of several biosimilar products in Israel"
mergers and acquisitions financial
"aims to secure new mergers and acquisitions, business development"
Mergers and acquisitions are processes where companies combine or one company purchases another to grow or improve their business. Think of it like two teams joining forces or one team buying out another to become stronger and more competitive. These activities matter to investors because they can influence a company's value, future growth, and overall market position.
FAQ
What does Kamada Ltd. (KMDA) announce in this Form 6-K?
Kamada Ltd. announces it will release first quarter 2026 financial results on May 13, 2026, before the U.S. market opens. The company will also host an investment community conference call that morning to discuss the results and answer questions from participants.
When is Kamada’s Q1 2026 earnings release and conference call?
Kamada plans to release Q1 2026 financial results on May 13, 2026, before U.S. markets open. Management will hold a conference call the same day at 8:30am Eastern Time to review the results and engage with shareholders and other interested parties.
How can investors join Kamada’s May 13, 2026 conference call?
Investors can join by dialing 1-877-407-0792 from the U.S., 1-809-406-247 from Israel, or 1-201-689-8263 internationally, using conference ID 13760232. The call will also be webcast live online at the provided Viavid webcast link.
What is Kamada Ltd.’s core business focus?
Kamada is a global biopharmaceutical company specializing in specialty plasma-derived therapies for rare and serious conditions. It markets multiple FDA-approved plasma-derived products and leverages manufacturing, research, and development expertise to advance additional product candidates addressing areas of significant unmet medical need.
Who controls Kamada Ltd. (KMDA) according to this filing?
FIMI Opportunity Funds is identified as Kamada’s controlling shareholder, beneficially owning approximately 38% of the company’s outstanding ordinary shares. This significant stake aligns FIMI closely with the company’s long-term strategy, growth initiatives, and overall corporate direction described in the disclosure.
What are Kamada’s main strategic growth pillars?
Kamada’s strategy focuses on four pillars: organic growth of its commercial plasma-derived portfolio, distribution of third-party products in Israel and MENA, expansion of plasma collection operations, and pursuing mergers, acquisitions, in-licensing, and collaborations to enhance its marketed portfolio and support long-term profitable growth.